SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Fibroblast growth factor-23 (FGF-23) as a prognostic marker for chronic kidney disease (CKD)	FGF-23 protein levels could help predict prognosis in patients with CKD. In 3,879 patients with stage 2–4 CKD, higher FGF-23 plasma protein levels were associated with greater risk for end-stage renal disease (ESRD) and mortality ($p<0.001$). Next steps include determining whether greater FGF-23 levels are a surrogate biomarker or directly linked to the increased risk of ESRD and mortality in CKD patients. *SciBX* 4(25); doi:10.1038/scibx.2011.726 Published online June 23, 2011	Patent and licensing status undisclosed	Isakova, T. *et al. JAMA*; published online June 15, 2011; doi:10.1001/jama.2011.826 **Contact:** Myles Wolf, University of Miami, Miami, Fla. e-mail: mwolf2@med.miami.edu